NASDAQ · Medical - Pharmaceuticals

RNTX (RNTX) Stock

$0.73 -4.62% NASDAQ: RNTX Healthcare

Valuation

MetricValue
Price$0.73
Market Cap$20.48M
P/E Ratio-0.59
P/B Ratio1.90
P/S Ratio0.00
EPS (TTM)$-1.96
52-Week High$2.18
52-Week Low$0.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-294.12%
ROA-208.33%
ROCE-129.41%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.42
Current Ratio0.67

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$0$0$0$-65.0M$-22.0M
Net Profit$0$0$0$-63.0M$-50.0M
EPS$-5.89$-6.02$-3.42$-3.51$-1.96
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$48.0M$22.0M$106.0M$69.0M$24.0M
Total Liabilities$5.0M$3.0M$99.0M$15.0M$7.0M
Cash$4.0M$5.0M$17.0M$13.0M$3.0M
Borrowings$0$0$0$0$0

Latest News

Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial MT Newswires · Jul 21, 2026 Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries GlobeNewswire · Jul 21, 2026 All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy Zacks · Jun 17, 2026 Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom GlobeNewswire · Jun 11, 2026 Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option GlobeNewswire · May 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-24.0M$-25.0M$-20.0M$-22.0M$-19.0M
Investing Cash Flow$-36.0M$26.0M$16.0M$0$0
Financing Cash Flow$0$0$16.0M$7.0M$0
Net Cash Flow$-4.0M$2.0M$12.0M$-4.0M$-10.0M
Free Cash Flow$-24.0M$-25.0M$-20.0M$-22.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-58.92%
Quick Ratio0.40
Interest Coverage—
Return 1Y-32.41%
Return 3Y-51.23%
Return 5Y-95.49%

Ownership

Insiders Held5.37%
Institutions Held20.85%
Institutions Float Held22.04%
Institutional HolderSharesReport Date
Voss Capital, LP4,388,3622026-03-31
Bios Capital Management, LP 1,982,3752026-03-31
Vanguard Capital Management LLC998,5212026-03-31
University of Texas/Texas AM Investment Managment Co511,6102026-03-31
Cable Car Capital, LP420,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
BCABBioAtla, Inc. $3.40 +0.89% -0.08 $4.29M 0.00%
BEAT $0.50 +0.98% -1.48 $17.10M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%

About RNTX

RNTX is led by CEO James Brian Windsor, employs 11 people, headquartered in US, publicly traded since 2017.

RNTX stock trades at $0.73 with a market capitalization of $20.48M. The stock is valued at a price-to-earnings (P/E) ratio of -0.59, price-to-book of 1.90, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.73 and $2.18, and currently trades 66.5% below its 52-week high.

On profitability, RNTX generates a return on equity (ROE) of -294.12%, return on capital employed of -129.41%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides